Strongbridge Biopharma (NASDAQ:SBBP) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday.

Several other equities analysts have also commented on SBBP. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. Janney Montgomery Scott upped their target price on shares of Strongbridge Biopharma to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. JMP Securities upped their target price on shares of Strongbridge Biopharma from $10.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 9th. Finally, HC Wainwright set a $18.00 target price on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Thursday, August 9th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Strongbridge Biopharma presently has a consensus rating of “Hold” and an average price target of $14.75.

Shares of SBBP stock opened at $5.23 on Monday. The company has a current ratio of 3.38, a quick ratio of 3.11 and a debt-to-equity ratio of 8.76. Strongbridge Biopharma has a one year low of $3.85 and a one year high of $9.25. The company has a market capitalization of $271.85 million, a PE ratio of -3.72 and a beta of -0.36.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.06). The firm had revenue of $5.35 million for the quarter, compared to analysts’ expectations of $5.48 million. Equities analysts expect that Strongbridge Biopharma will post -1.89 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its stake in Strongbridge Biopharma by 176.3% during the first quarter. Wells Fargo & Company MN now owns 123,348 shares of the biotechnology company’s stock valued at $1,091,000 after buying an additional 78,708 shares during the period. Northern Trust Corp boosted its stake in Strongbridge Biopharma by 3.6% during the first quarter. Northern Trust Corp now owns 237,053 shares of the biotechnology company’s stock valued at $2,098,000 after buying an additional 8,212 shares during the period. BlackRock Inc. boosted its stake in Strongbridge Biopharma by 25.4% during the first quarter. BlackRock Inc. now owns 1,795,693 shares of the biotechnology company’s stock valued at $15,892,000 after buying an additional 363,328 shares during the period. Millennium Management LLC boosted its stake in Strongbridge Biopharma by 675.3% during the first quarter. Millennium Management LLC now owns 137,880 shares of the biotechnology company’s stock valued at $1,220,000 after buying an additional 120,095 shares during the period. Finally, Alps Advisors Inc. bought a new stake in Strongbridge Biopharma during the second quarter valued at $396,000. 67.33% of the stock is currently owned by hedge funds and other institutional investors.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Read More: Dow Jones Industrial Average (DJIA)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.